<PAGE> 1
SCHEDULE 14A
(RULE 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO. )
Filed by the registrant [X]
Filed by a party other than the registrant [ ]
Check the appropriate box:
[ ] Preliminary proxy statement. [ ] Confidential, for use of the
Commission only (as permitted by
Rule 14a-6(e)(2)).
[ ] Definitive proxy statement.
[X] Definitive additional materials.
[ ] Soliciting material pursuant to Rule 14a-11(c) or Rule 14a-12.
NORTHFIELD LABORATORIES INC.
--------------------------------------------------------------------------------
(Name of Registrant as Specified in Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of filing fee (check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
(1) Title of each class of securities to which transaction applies:
--------------------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
--------------------------------------------------------------------------------
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
filing fee is calculated and state how it was determined):
--------------------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
--------------------------------------------------------------------------------
(5) Total fee paid:
--------------------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
--------------------------------------------------------------------------------
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the form or schedule and the date of its filing.
(1) Amount Previously Paid:
--------------------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
--------------------------------------------------------------------------------
(3) Filing Party:
--------------------------------------------------------------------------------
(4) Date Filed:
--------------------------------------------------------------------------------
<PAGE> 2
NORTHFIELD LABORATORIES INC.
1560 SHERMAN AVENUE, SUITE 1000
EVANSTON, IL 60201
(847) 864-3500
WWW.NORTHFIELDLABS.COM
AT NORTHFIELD LABORATORIES: AT THE FINANCIAL RELATIONS BOARD:
Richard DeWoskin General Information Analysts/Investors
Chief Executive Officer Leslie Hunziker Leslie Loyet
(847) 864-3500 (312) 266-7800 (312) 266-7800
FOR IMMEDIATE RELEASE
TUESDAY, SEPTEMBER 26, 2000
NORTHFIELD LABS AND C. ROBERT COATES AND MANAGEMENT INSIGHTS
REACH AGREEMENT
EVANSTON, ILLINOIS, SEPTEMBER 26, 2000-NORTHFIELD LABORATORIES INC. (NASDAQ:
NFLD) announced today that it has reached agreement with C. Robert Coates and
Management Insights, Inc. on a series of steps designed to promote increased
understanding and investor awareness regarding Northfield and its
PolyHeme(TM) blood substitute product.
Northfield's senior management, Richard E. DeWoskin and Steven A. Gould, and Mr.
Coates met today to discuss ways to enhance the flow of information available to
Northfield's shareholders and others in the scientific, business and investment
communities. Northfield indicated that it planned to increase significantly the
resources devoted to investor relations activities and to consider additional
steps to provide enhanced information to its public investors. In addition,
Northfield agreed to explore expanding its board of directors to include one or
more additional independent directors with substantial FDA regulatory experience
or a background in the pharmaceutical industry.
Northfield also provided clarification that shareholders attending its upcoming
annual meeting of shareholders would be free to ask questions and make
statements. Arrangements have been made to permit those shareholders attending
the annual meeting in person to view the business update presentation being
broadcast on the Internet at the meeting site following the conclusion of the
meeting. If the webcast format works well at the annual meeting, Northfield may
schedule periodic webcasts to update shareholders on the Company's progress.
Mr. Coates and Northfield's senior management agreed to meet periodically in the
future to review the status of the steps being implemented by Northfield.
Following the meeting, Mr. Coates and Management Insights indicated that they
had determined to withdraw their proposed slate of directors and will not
solicit proxies in connection with the 2000 annual meeting.
FOR MORE INFORMATION ON NORTHFIELD LABORATORIES INC. VIA FACSIMILE AT NO COST,
SIMPLY DIAL 1-800-PRO-INFO AND ENTER THE COMPANY CODE NFLD.
VISIT THE NORTHFIELD WEBSITE AT WWW.NORTHFIELDLABS.COM
